CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

InnoCare's Orelabrutinib Combination Shows 89.5% Response Rate in Phase 2 Marginal Zone Lymphoma Trial

By Public Technologies
  • InnoCare Pharma presented results from three orelabrutinib studies at the European Society for Medical Oncology Congress 2026.
  • A Phase 2 trial combining orelabrutinib with zuberitamab showed durable responses in previously untreated marginal zone lymphoma, with manageable safety.
  • Another Phase 2 study showed sustained benefit in relapsed or refractory chronic lymphocytic leukemia, with favorable long-term safety.
  • A retrospective study found orelabrutinib with rituximab deepened responses during maintenance treatment for intermediate- or high-risk marginal zone lymphoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610272030PRIMZONEFULLFEED9854775) on October 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk